Please use this identifier to cite or link to this item: http://nopr.niscair.res.in/handle/123456789/6062
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRai, Rajnish Kumar-
dc.date.accessioned2009-10-01T06:53:18Z-
dc.date.available2009-10-01T06:53:18Z-
dc.date.issued2008-07-
dc.identifier.issn0975-1076 (Online); 0971-7544 (Print)-
dc.identifier.urihttp://hdl.handle.net/123456789/6062-
dc.description301-317en_US
dc.description.abstractThe full scale compliance of TRIPS Agreement essentially represents a big step in the opposite direction as it effectively ended more than three decades of protection for Indian companies and terminated legal ‘reverse engineering’. The new patent regime throws a new challenge to the Indian pharmaceutical industry to maintain its competitiveness and profitability. This study investigates emerging firm strategies of the Indian pharmaceutical companies to overcome the challenge posed by new patent regime. The study concludes that the industry is witnessing a transition phase, and is undergoing consolidation and restructuring. The industry is adopting a mix of competitive and collaborative business and R&D strategies in the emerging business environmenten_US
dc.language.isoen_USen_US
dc.publisherCSIRen_US
dc.sourceJIPR Vol.13(4) [July 2008]en_US
dc.subjectTRIPSen_US
dc.subjectIndian pharmaceutical industryen_US
dc.subjectbusiness strategiesen_US
dc.subjectR&Den_US
dc.titleBattling with TRIPS: Emerging Firm Strategies of Indian Pharmaceutical Industry Post-TRIPSen_US
dc.typeArticleen_US
Appears in Collections:JIPR Vol.13(4) [July 2008]

Files in This Item:
File Description SizeFormat 
JIPR 13(4) 301-317.pdf224.43 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.